Amarkumar Dhirajlal Rajgor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amarkumar Dhirajlal Rajgor has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
David Winston Hamilton
Newcastle upon Tyne Hospitals NHS Foundation Trust
8 shared publications- Muhammad Shahid Iqbal
Northern Centre for Cancer Care, Newcastle upon Tyne, UK; Honorary Senior Clinical Lecturer, Newcastle University, Newcastle upon Tyne, UK
5 shared publications Aileen Mill
Newcastle University
4 shared publicationsBoguslaw Obara
Newcastle University
4 shared publicationsStephen Rushton
Newcastle University
4 shared publicationsColin Gillespie
School of Mathematics, Newcastle University, Newcastle-Upon-Tyne, UK NE1 7RU
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- p. 1-10
Predicting radiation-induced xerostomia in head and neck cancer: a critical review of radiomics, machine learning and methodological quality
Objective: To evaluate the predictive performance, methodological quality and clinical readiness of radiomics and machine learning approaches for predicting radiation-induced xerostomia. Methods: A structured narrative review was conducted. PubMed and Embase were searched for studies evaluating radiomics, machine learning and deep learning approaches for predicting xerostomia following head and neck radiotherapy. Methodological quality was assessed using the Radiomics Quality Score. Results: Twenty-two eligible studies, with cohorts ranging from 19 to 1208 patients, were identified. Delta-radiomics and deep learning approaches generally demonstrated the strongest predictive performance, although gains over conventional models were typically modest. Mean Radiomics Quality Score was 14 out of 36, with common limitations including limited external validation, absence of prospective studies, lack of open science and no cost-effectiveness analyses. Conclusion: Radiomics and machine learning show potential as adjuncts to existing xerostomia prediction models; however, methodological limitations and poor generalisability remain barriers to routine clinical implementation.
- 9 November 2026
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- p. 1-10
Open AccessPredicting radiation-induced xerostomia in head and neck cancer: a critical review of radiomics, machine learning and methodological quality
Objective: To evaluate the predictive performance, methodological quality and clinical readiness of radiomics and machine learning approaches for predicting radiation-induced xerostomia. Methods: A structured narrative review was conducted. PubMed and Embase were searched for studies evaluating radiomics, machine learning and deep learning approaches for predicting xerostomia following head and neck radiotherapy. Methodological quality was assessed using the Radiomics Quality Score. Results: Twenty-two eligible studies, with cohorts ranging from 19 to 1208 patients, were identified. Delta-radiomics and deep learning approaches generally demonstrated the strongest predictive performance, although gains over conventional models were typically modest. Mean Radiomics Quality Score was 14 out of 36, with common limitations including limited external validation, absence of prospective studies, lack of open science and no cost-effectiveness analyses. Conclusion: Radiomics and machine learning show potential as adjuncts to existing xerostomia prediction models; however, methodological limitations and poor generalisability remain barriers to routine clinical implementation.
- Open Access
- 13 October 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e94888
Cochlear Implant Referrals in Adults With Severe-to-Profound Hearing Loss in the United Kingdom (CIRCA-2): Protocol for a Repeat National Multicenter Retrospective Observational Study
Background: Cochlear implantation (CI) is a highly effective intervention for adults with severe-to-profound hearing loss, yet uptake across the United Kingdom remains low despite clear National Institute for Health and Care Excellence (NICE 2019) guidance and well-established clinical benefits. The original Cochlear Implant Referral Criteria Audit (CIRCA-1) identified marked inequities in access to CIs in 2022, with lower referral rates among older adults, males, and individuals from socioeconomically deprived areas, alongside individuals from minority ethnic backgrounds being less likely to be informed of their eligibility for referral. Since then, national awareness initiatives and the expansion of the existing local “CI Champions” scheme have aimed to address these inequities, improve awareness of CI candidacy, and improve the quality of discussions with patients about options for CI referral. This repeat assessment aims to assess the success of these interventions to identify improvements in access to CIs as well as persisting barriers. Objective: CIRCA-2 is a national, multicenter, retrospective observational audit designed to re-evaluate adult CI referral pathways and measure progress since the first audit cycle. Methods: The study will include adults assessed in secondary-care ear, nose, throat, and audiology departments between July and December 2025 whose audiometric thresholds meet NICE TA566 criteria. Participating centers will identify eligible patients using the British Cochlear Implant Group Crystal Report within Auditbase, and anonymized demographic, audiometric, and service-level data will be extracted. The primary outcomes are the proportions of patients meeting NICE TA566 criteria who were informed of their eligibility and referred for CI assessment, with comparisons made to CIRCA-1 data. Secondary analyses will examine adherence to national standards and predictors of discussion and referral using multivariable modeling. In addition, the study will assess the number of patients within criteria for the Comparing Cochlear Implants With Hearing Aids in Adults (COACH) trial and those meeting CI criteria in one ear only. Results: Retrospective data for the period July 1 to December 31, 2025, were collected between January and March 2026. Eighty-three sites submitted data relating to 15,060 patients. Data analysis is projected to be complete by October 2026, with publication of final results expected in early 2027. Conclusions: By quantifying change over time, CIRCA-2 will provide an updated national picture of CI referral practice, highlight any persisting barriers, and inform future strategies to promote equitable access to CIs.
- 13 October 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e94888
Open AccessCochlear Implant Referrals in Adults With Severe-to-Profound Hearing Loss in the United Kingdom (CIRCA-2): Protocol for a Repeat National Multicenter Retrospective Observational Study
Background: Cochlear implantation (CI) is a highly effective intervention for adults with severe-to-profound hearing loss, yet uptake across the United Kingdom remains low despite clear National Institute for Health and Care Excellence (NICE 2019) guidance and well-established clinical benefits. The original Cochlear Implant Referral Criteria Audit (CIRCA-1) identified marked inequities in access to CIs in 2022, with lower referral rates among older adults, males, and individuals from socioeconomically deprived areas, alongside individuals from minority ethnic backgrounds being less likely to be informed of their eligibility for referral. Since then, national awareness initiatives and the expansion of the existing local “CI Champions” scheme have aimed to address these inequities, improve awareness of CI candidacy, and improve the quality of discussions with patients about options for CI referral. This repeat assessment aims to assess the success of these interventions to identify improvements in access to CIs as well as persisting barriers. Objective: CIRCA-2 is a national, multicenter, retrospective observational audit designed to re-evaluate adult CI referral pathways and measure progress since the first audit cycle. Methods: The study will include adults assessed in secondary-care ear, nose, throat, and audiology departments between July and December 2025 whose audiometric thresholds meet NICE TA566 criteria. Participating centers will identify eligible patients using the British Cochlear Implant Group Crystal Report within Auditbase, and anonymized demographic, audiometric, and service-level data will be extracted. The primary outcomes are the proportions of patients meeting NICE TA566 criteria who were informed of their eligibility and referred for CI assessment, with comparisons made to CIRCA-1 data. Secondary analyses will examine adherence to national standards and predictors of discussion and referral using multivariable modeling. In addition, the study will assess the number of patients within criteria for the Comparing Cochlear Implants With Hearing Aids in Adults (COACH) trial and those meeting CI criteria in one ear only. Results: Retrospective data for the period July 1 to December 31, 2025, were collected between January and March 2026. Eighty-three sites submitted data relating to 15,060 patients. Data analysis is projected to be complete by October 2026, with publication of final results expected in early 2027. Conclusions: By quantifying change over time, CIRCA-2 will provide an updated national picture of CI referral practice, highlight any persisting barriers, and inform future strategies to promote equitable access to CIs.
- Open Access
- 8 July 2026
- Published by Wiley in Clinical Otolaryngology
- Vol. 51 (6) , 867-874
Laryngeal Cancer Survival in Northern United Kingdom: A Multi‐Centre Retrospective Observational Study
Objectives: Laryngeal cancer incidence has risen globally, yet survival outcomes have shown limited improvement over recent decades. This study evaluated contemporary outcomes across multiple centres in Northern UK and examined stage‐ and treatment‐specific survival. Design: Multi‐centre retrospective observational study. Setting and Participants: Data were collected for 2028 patients with biopsy‐proven squamous cell carcinoma of the larynx treated with curative intent between 2015 and 2021 across six tertiary head and neck cancer centres (Newcastle, Glasgow, Liverpool, Sheffield, Leeds, and Middlesbrough). Main Outcome Measures: Overall survival (OS) and disease‐specific survival (DSS) were estimated using Kaplan–Meier analysis and compared using log‐rank testing. Results: Median follow‐up was 40 months (mean age 66.8 years; 81% male). Overall mortality was 41% and disease‐specific mortality 20%. Five‐year OS declined with advancing stage: 72.0% (T1), 54.5% (T2), 50.6% (T3), and 45.2% (T4). In unadjusted analyses, surgery in T1 disease was associated with higher survival (5‐year DSS 93.6% vs. 88.5%), while in advanced disease chemoradiotherapy was associated with the highest DSS (5‐year DSS 70.2%), although differences were not statistically significant. No significant differences in DSS were observed across year of diagnosis (2015–2021). Conclusions: Survival outcomes for laryngeal cancer remain poor and have shown limited improvement over time. These findings provide important real‐world insights into contemporary outcomes and highlight the need for earlier detection, prevention strategies, and prospective collaborative research to improve future outcomes.
- 8 July 2026
- Published by Wiley in Clinical Otolaryngology
- Vol. 51 (6) , 867-874
Open AccessLaryngeal Cancer Survival in Northern United Kingdom: A Multi‐Centre Retrospective Observational Study
Objectives: Laryngeal cancer incidence has risen globally, yet survival outcomes have shown limited improvement over recent decades. This study evaluated contemporary outcomes across multiple centres in Northern UK and examined stage‐ and treatment‐specific survival. Design: Multi‐centre retrospective observational study. Setting and Participants: Data were collected for 2028 patients with biopsy‐proven squamous cell carcinoma of the larynx treated with curative intent between 2015 and 2021 across six tertiary head and neck cancer centres (Newcastle, Glasgow, Liverpool, Sheffield, Leeds, and Middlesbrough). Main Outcome Measures: Overall survival (OS) and disease‐specific survival (DSS) were estimated using Kaplan–Meier analysis and compared using log‐rank testing. Results: Median follow‐up was 40 months (mean age 66.8 years; 81% male). Overall mortality was 41% and disease‐specific mortality 20%. Five‐year OS declined with advancing stage: 72.0% (T1), 54.5% (T2), 50.6% (T3), and 45.2% (T4). In unadjusted analyses, surgery in T1 disease was associated with higher survival (5‐year DSS 93.6% vs. 88.5%), while in advanced disease chemoradiotherapy was associated with the highest DSS (5‐year DSS 70.2%), although differences were not statistically significant. No significant differences in DSS were observed across year of diagnosis (2015–2021). Conclusions: Survival outcomes for laryngeal cancer remain poor and have shown limited improvement over time. These findings provide important real‐world insights into contemporary outcomes and highlight the need for earlier detection, prevention strategies, and prospective collaborative research to improve future outcomes.
- 18 June 2026
- Published by Wiley in Head & Neck
- Vol. 48 (12) , 3320-3328
Impact of Soft Palate Involvement on the Outcome of Definitive (Chemo)radiotherapy for Tonsillar Squamous Cell Carcinoma
Background: To analyze the impact of soft palate involvement on survival outcomes of patients with tonsillar carcinoma treated with definitive (chemo)radiotherapy. Methods: A total of 402 patients treated between January 2010 and December 2023 were included. Results: Soft palate was involved in 170 patients. A complete response was achieved in 381 patients. Locoregional recurrence occurred in 26 patients (6.5%) and distant metastasis in 56 patients (13.9%). For the whole group, the 5‐year rates for local control, disease‐free survival, disease‐specific survival, and overall survival were 92.6%, 74.6%, 80.6%, and 74.8%, respectively. Smoking status, nodal stage, systemic treatment and soft palate involvement were identified as prognostic factors. The rate of distant metastasis was significantly higher in patients with soft palate involvement (19.4% vs. 9.9%; p = 0.0066). Conclusion: To the best of authors' knowledge, we report the first study to analyze the impact of soft palate involvement on outcomes for patients with tonsillar cancer treated with (chemo)radiotherapy. The incidence of local recurrence is low; however, the rate of distant metastasis is high and is significantly higher in patients with soft palate involvement.
- 18 June 2026
- Published by Wiley in Head & Neck
- Vol. 48 (12) , 3320-3328
Impact of Soft Palate Involvement on the Outcome of Definitive (Chemo)radiotherapy for Tonsillar Squamous Cell Carcinoma
Background: To analyze the impact of soft palate involvement on survival outcomes of patients with tonsillar carcinoma treated with definitive (chemo)radiotherapy. Methods: A total of 402 patients treated between January 2010 and December 2023 were included. Results: Soft palate was involved in 170 patients. A complete response was achieved in 381 patients. Locoregional recurrence occurred in 26 patients (6.5%) and distant metastasis in 56 patients (13.9%). For the whole group, the 5‐year rates for local control, disease‐free survival, disease‐specific survival, and overall survival were 92.6%, 74.6%, 80.6%, and 74.8%, respectively. Smoking status, nodal stage, systemic treatment and soft palate involvement were identified as prognostic factors. The rate of distant metastasis was significantly higher in patients with soft palate involvement (19.4% vs. 9.9%; p = 0.0066). Conclusion: To the best of authors' knowledge, we report the first study to analyze the impact of soft palate involvement on outcomes for patients with tonsillar cancer treated with (chemo)radiotherapy. The incidence of local recurrence is low; however, the rate of distant metastasis is high and is significantly higher in patients with soft palate involvement.
- 3 April 2026
- Published by Elsevier in Clinical Oncology
- Vol. 54, 104159
In Response to “Time-Dependent and Competing-Risk Considerations in Mandibular Osteoradionecrosis After Radiotherapy for Oral Cancer”
- 3 April 2026
- Published by Elsevier in Clinical Oncology
- Vol. 54, 104159
In Response to “Time-Dependent and Competing-Risk Considerations in Mandibular Osteoradionecrosis After Radiotherapy for Oral Cancer”
- Open Access
- 26 February 2026
- Published by Medip Academy in International Journal of Otorhinolaryngology and Head and Neck Surgery
Survival outcomes of parotid carcinomas treated with surgery and adjuvant radiation therapy
Background: Parotid cancers are a diverse histological group of cancers involving the parotid gland with varying effects of prognostic factors on treatment outcomes. The effect of adjuvant radiotherapy on the outcome in parotid cancers has always been debated in the past. The objective of current study was to measure the effect of prognostic factors and the survival outcomes of patients with primary parotid cancers treated with surgery and adjuvant radiotherapy. Methods: From January 2010 to December 2023, a total of 61 patients treated at Freeman Hospital, were included in the analysis. Data was collected and stratified according to age, gender, tumour staging, surgical margins, lymphovascular invasion (LVI), peri-neural invasion (PNI), extra nodal extension (ENE) and recurrence rate. All patients treated with surgery and adjuvant radiotherapy were included in the study. Patients with incomplete data, distant metastasis or those lost to follow up were excluded. The OS, DSS and RFS rates based on surgical margins, LVI, PNI and ENE were calculated. Results: The 5-year OS, DSS and RFS were 72.6%, 79.6% and 77.7%, respectively. Positive surgical margins did not influence the survival outcome in comparison to close or clear margins. Lower survival rates were noted for patients with ENE, although not reaching statistical significance. Conclusion: Though retrospective in nature, our study provides valuable information that close or involved surgical margins do not adversely affect the outcome for parotid cancers treated with surgery and adjuvant radiotherapy and that surgical re-resection might not be indicated in this patient population.
- 26 February 2026
- Published by Medip Academy in International Journal of Otorhinolaryngology and Head and Neck Surgery
Open AccessSurvival outcomes of parotid carcinomas treated with surgery and adjuvant radiation therapy
Background: Parotid cancers are a diverse histological group of cancers involving the parotid gland with varying effects of prognostic factors on treatment outcomes. The effect of adjuvant radiotherapy on the outcome in parotid cancers has always been debated in the past. The objective of current study was to measure the effect of prognostic factors and the survival outcomes of patients with primary parotid cancers treated with surgery and adjuvant radiotherapy. Methods: From January 2010 to December 2023, a total of 61 patients treated at Freeman Hospital, were included in the analysis. Data was collected and stratified according to age, gender, tumour staging, surgical margins, lymphovascular invasion (LVI), peri-neural invasion (PNI), extra nodal extension (ENE) and recurrence rate. All patients treated with surgery and adjuvant radiotherapy were included in the study. Patients with incomplete data, distant metastasis or those lost to follow up were excluded. The OS, DSS and RFS rates based on surgical margins, LVI, PNI and ENE were calculated. Results: The 5-year OS, DSS and RFS were 72.6%, 79.6% and 77.7%, respectively. Positive surgical margins did not influence the survival outcome in comparison to close or clear margins. Lower survival rates were noted for patients with ENE, although not reaching statistical significance. Conclusion: Though retrospective in nature, our study provides valuable information that close or involved surgical margins do not adversely affect the outcome for parotid cancers treated with surgery and adjuvant radiotherapy and that surgical re-resection might not be indicated in this patient population.
- 24 January 2026
- Published by Elsevier in Clinical Oncology
- Vol. 52, 104064
High Incidence of Mandibular Osteoradionecrosis After Radiotherapy for Oral Cavity: Time for Rebalancing Risks and Benefits
- 24 January 2026
- Published by Elsevier in Clinical Oncology
- Vol. 52, 104064
High Incidence of Mandibular Osteoradionecrosis After Radiotherapy for Oral Cavity: Time for Rebalancing Risks and Benefits
- Open Access
Radiomics from Routine CT and PET/CT Imaging in Laryngeal Squamous Cell Carcinoma: A Systematic Review with Radiomics Quality Score Assessment
Background/Objectives: Radiomics, the high-throughput extraction of quantitative features from medical imaging, offers a promising method for identifying laryngeal cancer imaging biomarkers. We aim to systematically review the literature on radiomics in laryngeal squamous cell carcinoma, assessing applications in tumour staging, prognosis, recurrence prediction, and treatment response evaluation. PROSPERO ID: CRD420251117983. Methods: MEDLINE and EMBASE databases were searched in May 2025. Inclusion criteria: studies published between 1 January 2010 and 31 January 2024, extracted radiomic features from CT, PET/CT, or MRI, and analysed outcomes related to diagnosis, staging, survival, recurrence, or treatment response in laryngeal cancer. Exclusion criteria: case reports, abstracts, editorials, reviews, or conference proceedings, exclusive focus on preclinical or animal models, lack of a clear radiomics methodology, or did not include imaging-based feature extraction. Results were synthesised narratively by modelling objective, alongside formal assessment of methodological quality using the Radiomics Quality Score (RQS). Results: Twenty studies met the inclusion criteria, with most using CT-based radiomics. Seven incorporated PET/CT. Radiomic models demonstrated moderate-to-high accuracy across tasks including T-staging, thyroid cartilage invasion, survival prediction, and local failure. Key predictive features included first-order entropy, skewness, and texture metrics such as size zone non-uniformity and GLCM correlation. Methodological variability, limited external validation, and small samples were frequent limitations. Conclusions: Radiomics holds strong promise as a non-invasive biomarker for laryngeal cancer. However, methodological heterogeneity identified through formal quality assessment indicates that improved standardisation, reproducibility, and multicentre validation are required before widespread clinical implementation.
Open AccessRadiomics from Routine CT and PET/CT Imaging in Laryngeal Squamous Cell Carcinoma: A Systematic Review with Radiomics Quality Score Assessment
Background/Objectives: Radiomics, the high-throughput extraction of quantitative features from medical imaging, offers a promising method for identifying laryngeal cancer imaging biomarkers. We aim to systematically review the literature on radiomics in laryngeal squamous cell carcinoma, assessing applications in tumour staging, prognosis, recurrence prediction, and treatment response evaluation. PROSPERO ID: CRD420251117983. Methods: MEDLINE and EMBASE databases were searched in May 2025. Inclusion criteria: studies published between 1 January 2010 and 31 January 2024, extracted radiomic features from CT, PET/CT, or MRI, and analysed outcomes related to diagnosis, staging, survival, recurrence, or treatment response in laryngeal cancer. Exclusion criteria: case reports, abstracts, editorials, reviews, or conference proceedings, exclusive focus on preclinical or animal models, lack of a clear radiomics methodology, or did not include imaging-based feature extraction. Results were synthesised narratively by modelling objective, alongside formal assessment of methodological quality using the Radiomics Quality Score (RQS). Results: Twenty studies met the inclusion criteria, with most using CT-based radiomics. Seven incorporated PET/CT. Radiomic models demonstrated moderate-to-high accuracy across tasks including T-staging, thyroid cartilage invasion, survival prediction, and local failure. Key predictive features included first-order entropy, skewness, and texture metrics such as size zone non-uniformity and GLCM correlation. Methodological variability, limited external validation, and small samples were frequent limitations. Conclusions: Radiomics holds strong promise as a non-invasive biomarker for laryngeal cancer. However, methodological heterogeneity identified through formal quality assessment indicates that improved standardisation, reproducibility, and multicentre validation are required before widespread clinical implementation.
- Open Access
- 6 October 2025
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 140 (1) , 31-36
When research data meet reality: contrasting advanced laryngeal cancer outcomes in The Cancer Imaging Archive (TCIA) and a United Kingdom regional cohort
Objectives: Clinical trials provide valuable treatment insights but often fail to represent real-world outcomes. This is particularly true for advanced laryngeal cancer patients, who face significant co-morbidities and socioeconomic challenges. This study evaluates whether outcomes from research datasets in The Cancer Imaging Archive reflect real-world survival in a regional cohort from North-East England. Methods: This retrospective analysis compares outcomes between The Cancer Imaging Archive (n = 198) and North-East England (n = 222) cohorts. Demographics, treatment modalities and five-year disease-specific survival were assessed via Kaplan–Meier curves and Cox regression. Results: North-East England had a lower five-year disease-specific survival (59.2 per cent vs. 76.9 per cent; p = 0.0018) and was characterised by greater co-morbidity burden and upfront surgery with adjuvant therapy (51 per cent), whereas The Cancer Imaging Archive patients received upfront chemoradiotherapy (53 per cent) or radiotherapy alone (41 per cent). Conclusion: The poorer real-world outcomes reflect the challenges of generalising research data to heterogeneous populations. Bridging the gap between research efficacy and real-world effectiveness is critical to delivering equitable care for advanced laryngeal cancer.
- 6 October 2025
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 140 (1) , 31-36
Open AccessWhen research data meet reality: contrasting advanced laryngeal cancer outcomes in The Cancer Imaging Archive (TCIA) and a United Kingdom regional cohort
Objectives: Clinical trials provide valuable treatment insights but often fail to represent real-world outcomes. This is particularly true for advanced laryngeal cancer patients, who face significant co-morbidities and socioeconomic challenges. This study evaluates whether outcomes from research datasets in The Cancer Imaging Archive reflect real-world survival in a regional cohort from North-East England. Methods: This retrospective analysis compares outcomes between The Cancer Imaging Archive (n = 198) and North-East England (n = 222) cohorts. Demographics, treatment modalities and five-year disease-specific survival were assessed via Kaplan–Meier curves and Cox regression. Results: North-East England had a lower five-year disease-specific survival (59.2 per cent vs. 76.9 per cent; p = 0.0018) and was characterised by greater co-morbidity burden and upfront surgery with adjuvant therapy (51 per cent), whereas The Cancer Imaging Archive patients received upfront chemoradiotherapy (53 per cent) or radiotherapy alone (41 per cent). Conclusion: The poorer real-world outcomes reflect the challenges of generalising research data to heterogeneous populations. Bridging the gap between research efficacy and real-world effectiveness is critical to delivering equitable care for advanced laryngeal cancer.